Journal article
Cohort profile: the multigeneration Respiratory Health in Northern Europe, Spain and Australia (RHINESSA) cohort
C Svanes, A Johannessen, RJ Bertelsen, S Dharmage, B Benediktsdottir, L Bråbäck, T Gislason, M Holm, O Jõgi, CJ Lodge, A Malinovschi, J Martinez-Moratalla, A Oudin, JL Sánchez-Ramos, S Timm, C Janson, FG Real, V Schlünssen
BMJ Open | BMJ PUBLISHING GROUP | Published : 2022
Open access
Abstract
Purpose The Respiratory Health in Northern Europe, Spain and Australia (RHINESSA) cohort was established to (1) investigate how exposures before conception and in previous generations influence health and disease, particularly allergies and respiratory health, (2) identify susceptible time windows and (3) explore underlying mechanisms. The ultimate aim is to facilitate efficient intervention strategies targeting multiple generations. Participants RHINESSA includes study participants of multiple generations from ten study centres in Norway (1), Denmark (1), Sweden (3), Iceland (1), Estonia (1), Spain (2) and Australia (1). The RHINESSA core cohort, adult offspring generation 3 (G3), was first..
View full abstractGrants
Awarded by Norges Astma- og Allergiforbund
Funding Acknowledgements
Coordination of the RHINESSA study has received funding from the Research Council of Norway (Grants No. 274767, 214123, 228174, 230 827 and 273838), ERC StG project BRuSH #804199, the European Union's Horizon 2020 research and innovation programme under grant agreement No. 633 212 (the ALEC Study WP2), the Bergen Medical Research Foundation, and the Western Norwegian Regional Health Authorities (Grants No. 912011, 911 892 and 911631). Study centres have further received local funding from the following: Bergen: the above grants for study establishment and co-ordination, and, in addition, World University Network (REF and Sustainability grants), Norwegian Labour Inspection, the Norwegian Asthma and Allergy Association and Trond Mohn Foundation (Grant ID BFS2017TMT02). Albacete and Huelva: Sociedad Espanola de Patologia Respiratoria (SEPAR) Fondo de Investigacion Sanitaria (FIS PS09). Goteborg, Umea and Uppsala: the Swedish Heart and Lung Foundation, the Swedish Asthma and Allergy Association. Reykjavik: Iceland University. Melbourne: Australian National Health and Medical Research Council (NHMRC) Project Grant ID1128450. Tartu: the Estonian Research Council (Grant No. PUT562). Arhus: The Danish Wood Foundation (Grant No. 444508795), the Danish Working Environment Authority (Grant No. 20150067134), Aarhus University (PhD scholarship).The RHINE study received funding by Norwegian Research Council, Norwegian Asthma and Allergy Association, Danish Lung Association, Swedish Heart and Lung Foundation, Vardal Foundation for Health CareHealthcare Science and Allergy Research, Swedish Asthma and Allergy Association, Icelandic Research Council, and Estonian Science Foundation. The RHINE IV ongoing study has received funding from the Research Council of Norway project Life-GAP grant No. 300 765.Co-ordination of the ECRHS study has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 633 212 (the ALEC study), the Medical Research Council (ECRHS III) and the European Commission FP5 and FP7 (ECRHS I and II). The ECRHS IV ongoing study in the ten RHINESSA study centres has received funding from the European Union's Horizon 2020 research and innovation programme projects EPHOR under grant agreement No. 874 703 and European Research Council (ERC) project BRuSH under grant agreement No. 804199, and from the Research Council of Norway grant No. 273 838. Funding agencies for ECRHS I, II and III are reported in online supplement.